Systemic Infection with<i>Mycobacterium genavense</i>Following Immunosuppressive Therapy in a Patient Who Was Seronegative for Human Immunodeficiency Virus

Christian Bogdan(Friedrich-Alexander-Universität Erlangen-Nürnberg), Werner Solbach(University of Lübeck), Sabine Rüsch–Gerdes(Research Center Borstel - Leibniz Lung Center), Andrea Tannapfel(Leipzig University), Elvira Richter(Radboud University Nijmegen), Thomas Kirchner(Ludwig-Maximilians-Universität München), P. M. Kern(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Clinical Infectious Diseases
June 1, 1997
10.1086/513634
Cited by 35

Related Papers

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
|European Journal of Immunology|2019|996
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
Lymphocyte Circadian Clocks Control Lymph Node Trafficking and Adaptive Immune Responses
|Immunity|2017|461
Cutting Edge: Neutrophil Granulocyte Serves as a Vector for <i>Leishmania</i> Entry into Macrophages
|The Journal of Immunology|2004|429